RMC No. 83-2022: Updated VAT-Exempt Medicines List for Diabetes, Hypertension, Mental Illness, Cancer, and Kidney Disease Drugs

RMC No. 83-2022 updates the VAT-exempt medicines list under CREATE, covering diabetes, hypertension, mental illness, cancer, and kidney disease drugs. Businesses that manufacture, import, distribute, sell, prescribe, dispense, procure, or account for medicines must immediately review their VAT treatment because RMC No. 83-2022 confirms updates to the List of VAT-Exempt Medicines under Republic Act No. […]

RMC No. 68-2022: Updated VAT-Exempt Medicines List for Hypertension, Diabetes, Cancer, COVID-19 and Other Treatments

RMC No. 68-2022 updates the FDA-endorsed VAT-exempt medicines list under CREATE for key disease categories including COVID-19 and cancer. Pharmacies, hospitals, clinics, distributors, importers, and VAT-registered sellers of medicines must check whether their covered products are included in the updated VAT-exempt medicines list endorsed by the Food and Drug Administration, because qualifying medicines for hypertension, […]

RMC No. 59-2022: VAT-Exempt Medicines for Cancer and COVID-19 Treatment Under the CREATE Act

RMC No. 59-2022 updates the VAT-exempt medicine list under CREATE to include certain cancer and COVID-19 treatment medicines. Businesses selling, purchasing, prescribing, distributing, or accounting for qualified medicines for cancer and COVID-19 treatment must check whether their products are covered by the updated List of VAT-Exempt Medicines under Republic Act No. 11534, or the CREATE […]

RMC No. 56-2022: VAT-Exempt Medicines List Updated for Hypertension and COVID-19 Treatment Under CREATE Act

RMC No. 56-2022 updates the VAT-exempt medicines list for hypertension and COVID-19 treatment under the CREATE Act, requiring item-level VAT review. Pharmacies, hospitals, distributors, importers, clinics, and businesses selling or purchasing medicines for hypertension and COVID-19 treatment should immediately review their VAT treatment because RMC No. 56-2022 updates the List of VAT-Exempt Medicines under Republic […]

RMC No. 51-2022: Updated VAT-Exempt Medicines for COVID-19, Hypertension, and Cancer Under the CREATE Act

RMC No. 51-2022 updates the CREATE Act VAT-exempt medicine list for COVID-19, hypertension, and a corrected cancer medicine entry. Businesses dealing in covered medicines should immediately check whether their invoicing, VAT treatment, product master files, and pharmacy or distribution records reflect the latest VAT-exempt medicine list recognized for CREATE Act purposes. RMC No. 51-2022 confirms […]

RMC No. 47-2022: VAT-Exempt COVID-19 Medicines Under the CREATE Act and FDA-Endorsed Updates for Philippine Taxpayers

RMC No. 47-2022 publishes FDA-endorsed updates adding certain COVID-19 treatment medicines to the CREATE Act VAT-exempt medicines list. Businesses selling, purchasing, prescribing, distributing, or accounting for COVID-19 treatment medicines must check whether the medicine is covered by the FDA-endorsed updates to the list of VAT-exempt medicines under the CREATE Act, because covered medicines should be […]

RMC No. 30-2022: Updated VAT-Exempt Medicines List for Cancer, Diabetes, Hypertension, High Cholesterol, Mental Illness, and COVID-19

RMC No. 30-2022 updates the VAT-exempt medicines list under CREATE, covering specified medicines and requiring sellers to review VAT treatment. Pharmacies, hospitals, clinics, drug distributors, importers, and VAT-registered sellers of medicines must immediately verify whether the medicines they sell, dispense, import, or purchase are included in the updated VAT-exempt medicines list endorsed by the Food […]

RMC No. 81-2021: VAT Exemption for FDA-Listed Medicines, COVID-19 Drugs, Vaccines, and Medical Devices Under CREATE

RMC No. 81-2021 identifies FDA-listed VAT-exempt medicines, COVID-19 drugs, vaccines, and medical devices under CREATE, with key dates. Businesses selling or importing qualifying medicines, COVID-19 treatment drugs and vaccines, and COVID-19 medical devices must treat covered items as VAT-exempt based on the FDA-endorsed list of VAT-exempt products under the CREATE Act. The practical effect is […]

RMC No. 62-2020: VAT-Exempt Prescription Drugs for Diabetes, High Cholesterol and Hypertension Starting January 27, 2020

RMC No. 62-2020 lists VAT-exempt prescription drugs for diabetes, high cholesterol, and hypertension effective January 27, 2020. Pharmacies, hospitals, clinics, importers, distributors, and VAT-registered sellers must treat only the listed prescription drugs and medicines for diabetes, high cholesterol, and hypertension as VAT-exempt beginning January 27, 2020. The key business consequence of RMC No. 62-2020 is […]